Page 53 - Read Online

Page 18 of 20 Singh et al. Cancer Drug Resist. 2025;8:56

82. Zhu J, Li Q, Wu Z, Xu W, Jiang R. Circular RNA-mediated miRNA sponge & RNA binding protein in biological modulation of breast
cancer. Noncoding RNA Res. 2024;9:262-76. DOI PubMed PMC
83. Kai D, Yannian L, Yitian C, Dinghao G, Xin Z, Wu J. Circular RNA HIPK3 promotes gallbladder cancer cell growth by sponging
microRNA-124. Biochem Biophys Res Commun. 2018;503:863-9. DOI PubMed
84. Huang Y, Zhang C, Xiong J, Ren H. Emerging important roles of circRNAs in human cancer and other diseases. Genes Dis.
2021;8:412-23. DOI PubMed PMC
85. He AT, Liu J, Li F, Yang BB. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct
Target Ther. 2021;6:185. DOI PubMed PMC
86. Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol
Cancer. 2022;21:79. DOI PubMed PMC
87. Hirahata T, Ul Quraish R, Quraish AU, Ul Quraish S, Naz M, Razzaq MA. Liquid biopsy: a distinctive approach to the diagnosis and
prognosis of cancer. Cancer Inform. 2022;21:11769351221076062. DOI PubMed PMC
88. Verduci L, Strano S, Yarden Y, Blandino G. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment.
Mol Oncol. 2019;13:669-80. DOI PubMed PMC
89. Wang H, Zhang Y, Zhang H, et al. Liquid biopsy for human cancer: cancer screening, monitoring, and treatment. MedComm.
2024;5:e564. DOI PubMed PMC
90. Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6:404. DOI
PubMed PMC
91. Shi X, Wang B, Feng X, Xu Y, Lu K, Sun M. circRNAs and exosomes: a mysterious frontier for human cancer. Mol Ther Nucleic Acids.
2020;19:384-92. DOI PubMed PMC
92. Ge Q, Zhang ZY, Li SN, Ma JQ, Zhao Z. Liquid biopsy: comprehensive overview of circulating tumor DNA (Review). Oncol Lett.
2024;28:548. DOI PubMed PMC
93. Zhong P, Bai L, Hong M, et al. A comprehensive review on circulating cfRNA in plasma: implications for disease diagnosis and beyond.
Diagnostics. 2024;14:1045. DOI PubMed PMC
94. Wang S, Dong Y, Gong A, et al. Exosomal circRNAs as novel cancer biomarkers: challenges and opportunities. Int J Biol Sci.
2021;17:562-73. DOI PubMed PMC
95. Xu C, Jun E, Okugawa Y, et al. A circulating panel of circRNA biomarkers for the noninvasive and early detection of pancreatic ductal
adenocarcinoma. Gastroenterology. 2024;166:178-90.e16. DOI PubMed PMC
96. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131. DOI
PubMed PMC
97. Ma H, Bell KN, Loker RN. qPCR and qRT-PCR analysis: regulatory points to consider when conducting biodistribution and vector
shedding studies. Mol Ther Methods Clin Dev. 2021;20:152-68. DOI PubMed PMC
98. Gerdes L, Iwobi A, Busch U, Pecoraro S. Optimization of digital droplet polymerase chain reaction for quantification of genetically
modified organisms. Biomol Detect Quantif. 2016;7:9-20. DOI PubMed PMC
99. Hu T, Ke X, Yu Y, et al. NAPTUNE: nucleic acids and protein biomarkers testing via ultra-sensitive nucleases escalation. Nat Commun.
2025;16:1331. DOI PubMed PMC
100. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57-63. DOI PubMed PMC
101. Nazarov PV, Muller A, Kaoma T, et al. RNA sequencing and transcriptome arrays analyses show opposing results for alternative
splicing in patient derived samples. BMC Genomics. 2017;18:443. DOI PubMed PMC
102. Yang T, Zhang M, Zhang N. Modified Northern blot protocol for easy detection of mRNAs in total RNA using radiolabeled probes.
BMC Genomics. 2022;23:66. DOI PubMed PMC
103. Monné Rodríguez JM, Frisk AL, Kreutzer R, et al. European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology
Special Interest Group): review of in situ hybridization techniques for drug research and development. Toxicol Pathol. 2023;51:92-111.
DOI PubMed PMC
104. Goytain A, Ng T. NanoString nCounter Technology: high-throughput RNA validation. In: Li H, Elfman J, editors. Chimeric RNA. New
York: Springer US; 2020. pp. 125-39. DOI
105. Wang S, Qian L, Cao T, et al. Advances in the study of circRNAs in tumor drug resistance. Front Oncol. 2022;12:868363. DOI PubMed
PMC
106. Wang X, Wang L, Lin H, et al. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024;14:1303335.
DOI PubMed PMC
107. Turner N, Huang-Bartlett C, Kalinsky K, et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast
cancer during first-line treatment. Future Oncol. 2023;19:559-73. DOI PubMed
46